C10orf47 Inhibitors
The chemical class known as C10orf47 Inhibitors encompasses a range of compounds that modulate various signaling pathways and cellular processes, which in turn can influence the activity of the C10orf47 protein. This eclectic group of chemicals includes kinase inhibitors, proteasome inhibitors, and agents that induce cellular stress, all of which are known to affect cellular signaling cascades and protein interactions that could be relevant to the function of C10orf47.
Kinase inhibitors such as wortmannin, LY294002, U0126, SB203580, SP600125, rapamycin, PD98059, PP2, and ZM 336372 act by specifically targeting key enzymes in signal transduction pathways such as PI3K/AKT, MAPK/ERK, mTOR, Src, and RAF. These kinases play crucial roles in regulating cell proliferation, survival, and differentiation. By altering the activity of these kinases, the inhibitors can indirectly affect the regulation and function of C10orf47, assuming that its activity is modulated by one or more of these signaling pathways. For example, if C10orf47 were found to be downstream of PI3K/AKT signaling, then inhibiting PI3K with wortmannin or LY294002 would disrupt this pathway and consequently decrease C10orf47 activity.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is a potent phosphoinositide 3-kinase (PI3K) inhibitor. If C10orf47 is involved in PI3K/AKT signaling, wortmannin can inhibit this pathway, thereby reducing C10orf47 activity. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is another PI3K inhibitor, similar to wortmannin. It can inhibit the PI3K/AKT pathway, potentially decreasing the functional activity of C10orf47 if it interacts with this pathway. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 selectively inhibits p38 MAPK. Inhibition of p38 MAPK can alter the phosphorylation state of downstream proteins, potentially affecting C10orf47 function if it is regulated by p38 MAPK activity. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of c-Jun N-terminal kinase (JNK), which modulates transcription factors and other signaling molecules. If C10orf47 is a target of JNK signaling, SP600125 can alter its activity. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin specifically inhibits mTOR, which is involved in cell growth and proliferation. If C10orf47 is regulated by mTOR signaling, rapamycin can decrease its activity. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 is a selective inhibitor of MEK, which is upstream of ERK in the MAPK pathway. By inhibiting MEK, PD98059 can affect C10orf47 if it is part of the MAPK/ERK pathway. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $92.00 $223.00 | 30 | |
PP2 is a selective inhibitor of Src family tyrosine kinases. If C10orf47 activity is associated with Src signaling, PP2 can reduce its activity by inhibiting Src kinases. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $132.00 $1064.00 | 115 | |
Bortezomib inhibits the proteasome, which can lead to increased cellular stress and potentially disrupt protein homeostasis, affecting C10orf47 activity if it is stabilized by the proteasome. | ||||||
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $94.00 $349.00 | 114 | |
Thapsigargin is a SERCA pump inhibitor, leading to increased cytosolic calcium levels and ER stress. If C10orf47 function is calcium-dependent, thapsigargin can modulate its activity. | ||||||
Ibrutinib | 936563-96-1 | sc-483194 | 10 mg | $153.00 | 5 | |
Ibrutinib is a Bruton's tyrosine kinase (BTK) inhibitor. If C10orf47 is part of B cell receptor signaling, ibrutinib can reduce its activity by targeting BTK. | ||||||